BioMarin Pharmaceutical Inc. (BMRN)
- Previous Close
90.07 - Open
89.67 - Bid 89.15 x 200
- Ask 89.35 x 600
- Day's Range
88.97 - 90.18 - 52 Week Range
76.02 - 99.56 - Volume
285,313 - Avg. Volume
1,403,309 - Market Cap (intraday)
16.945B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
102.63 - EPS (TTM)
0.87 - Earnings Date Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
109.70
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
www.biomarin.comRecent News: BMRN
Performance Overview: BMRN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMRN
Valuation Measures
Market Cap
17.09B
Enterprise Value
17.12B
Trailing P/E
103.54
Forward P/E
33.56
PEG Ratio (5yr expected)
0.74
Price/Sales (ttm)
7.13
Price/Book (mrq)
3.45
Enterprise Value/Revenue
7.08
Enterprise Value/EBITDA
55.27
Financial Highlights
Profitability and Income Statement
Profit Margin
6.93%
Return on Assets (ttm)
1.63%
Return on Equity (ttm)
3.51%
Revenue (ttm)
2.42B
Net Income Avi to Common (ttm)
167.64M
Diluted EPS (ttm)
0.87
Balance Sheet and Cash Flow
Total Cash (mrq)
1.07B
Total Debt/Equity (mrq)
22.90%
Levered Free Cash Flow (ttm)
-25.9M
Research Analysis: BMRN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: BMRN
Analyst Report: BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
RatingNeutralPrice TargetAnalyst Report: BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
RatingNeutralPrice TargetAnalyst Report: BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
RatingBullishPrice TargetAnalyst Report: BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
RatingNeutralPrice Target